United-Guardian (UG) Q2 2025 earnings summary

Executive summary

• Q2 2025 net sales fell 16% year-over-year to $2.84M, and H1 sales declined 20% to $5.32M, mainly due to lower cosmetic ingredient sales in China and distributor inventory adjustments.

• Q2 2025 net income dropped to $627K from $956K, and H1 net income fell to $1.19M from $1.88M.

• Sequentially, Q2 net sales rose 14% and net income increased 12% from Q1 2025.

• Pharmaceutical net sales rose 3% in Q2 and 11% in H1, driven by Renacidin, while medical lubricant sales increased 12% in H1.

• Expansion into new markets and product lines is underway, with anticipated Natrajel sales in H2 2025.

Financial highlights

• Q2 2025 net sales: $2.84M (down from $3.39M); H1 2025 net sales: $5.32M (down from $6.65M).

• Q2 2025 net income: $627K (down from $956K); H1 2025 net income: $1.19M (down from $1.88M).

• Q2 2025 EPS: $0.14 (down from $0.21); H1 2025 EPS: $0.26 (down from $0.41).

• Q2 2025 gross margin: $1.50M (down from $1.83M); gross margin rate 53%, nearly flat year-over-year.

• Operating expenses rose 15% in Q2 and 13% in H1, mainly due to higher sales, marketing, and payroll costs.

Outlook and guidance

• Management expects working capital to remain sufficient for at least the next 12 months and plans to use cash for organic growth, strategic transactions, and inflation mitigation.

• Cosmetic ingredient sales are expected to improve in H2 2025 as distributor overstock is resolved.

• Anticipates initial sales of the Natrajel product line in H2 2025.

• New project aims to expand Renacidin into additional drug formularies.

• Effective tax rate expected to remain at 21% for 2025.